Basilea Pharmaceutica (BSLN) Stock Overview
A Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
BSLN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Basilea Pharmaceutica AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CHF 53.40 |
| 52 Week High | CHF 59.70 |
| 52 Week Low | CHF 37.50 |
| Beta | 0.43 |
| 1 Month Change | 13.98% |
| 3 Month Change | 17.49% |
| 1 Year Change | 32.51% |
| 3 Year Change | 12.66% |
| 5 Year Change | -0.37% |
| Change since IPO | -47.13% |
Recent News & Updates
Recent updates
Basilea Pharmaceutica (VTX:BSLN) Posted Healthy Earnings But There Are Some Other Factors To Be Aware Of
Aug 29
Emerging Markets And Drug Resistance Will Drive Global Expansion
Key Takeaways Expanding global sales of key anti-infective drugs and successful commercialization partnerships are driving top-line growth and increased royalty income. Strategic pipeline development, acquisitions, and a partnership-driven model support profit growth, regulatory momentum, and future market expansion.Benign Growth For Basilea Pharmaceutica AG (VTX:BSLN) Underpins Its Share Price
Jul 29Shareholders Will Probably Hold Off On Increasing Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For The Time Being
Apr 10Estimating The Intrinsic Value Of Basilea Pharmaceutica AG (VTX:BSLN)
Apr 04There May Be Underlying Issues With The Quality Of Basilea Pharmaceutica's (VTX:BSLN) Earnings
Feb 26Basilea Pharmaceutica (VTX:BSLN) Could Easily Take On More Debt
Feb 20Shareholders May Be More Conservative With Basilea Pharmaceutica AG's (VTX:BSLN) CEO Compensation For Now
Apr 18Does Basilea Pharmaceutica (VTX:BSLN) Deserve A Spot On Your Watchlist?
Sep 20Robust Earnings May Not Tell The Whole Story For Basilea Pharmaceutica (VTX:BSLN)
Feb 17Revenue Downgrade: Here's What Analysts Forecast For Basilea Pharmaceutica AG (VTX:BSLN)
Jul 01Analysts Expect Breakeven For Basilea Pharmaceutica AG (VTX:BSLN) Before Long
Mar 24If You Had Bought Basilea Pharmaceutica's (VTX:BSLN) Shares Three Years Ago You Would Be Down 19%
Feb 18Shareholder Returns
| BSLN | CH Biotechs | CH Market | |
|---|---|---|---|
| 7D | 3.5% | -1.4% | -0.2% |
| 1Y | 32.5% | 15.3% | 8.3% |
Return vs Industry: BSLN exceeded the Swiss Biotechs industry which returned 15.3% over the past year.
Return vs Market: BSLN exceeded the Swiss Market which returned 8.3% over the past year.
Price Volatility
| BSLN volatility | |
|---|---|
| BSLN Average Weekly Movement | 3.4% |
| Biotechs Industry Average Movement | 7.6% |
| Market Average Movement | 3.5% |
| 10% most volatile stocks in CH Market | 8.4% |
| 10% least volatile stocks in CH Market | 1.6% |
Stable Share Price: BSLN has not had significant price volatility in the past 3 months compared to the Swiss market.
Volatility Over Time: BSLN's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 180 | David Veitch | www.basilea.com |
Basilea Pharmaceutica AG is a Swiss commercial-stage biotech company focused on developing and commercializing treatments for severe bacterial and fungal infections. The company offers Cresemba (isavuconazole), an intravenous and oral antifungal for the treatment of invasive aspergillosis and mucormycosis; and Zevtera (ceftobiprole), an antibiotic for the treatment of pneumonia, Staphylococcus aureus bacteremia (SAB), and acute bacterial skin and skin structure infections (ABSSSI). The company also has a clinical-stage pipeline of anti-infective assets that include fosmanogepix, a broad-spectrum antifungal in phase 3 development for invasive mold and yeast infections; ceftibuten-ledaborbactam, a phase 3 - ready oral antibiotic for the treatment of complicated urinary tract infections (cUTI); BAL2062, a candidate for invasive aspergillosis currently advancing toward phase 2 clinical development; and BAL2420, a preclinical-stage antibiotic targeting severe Enterobacteriaceae infections.
Basilea Pharmaceutica AG Fundamentals Summary
| BSLN fundamental statistics | |
|---|---|
| Market cap | CHF 656.16m |
| Earnings (TTM) | CHF 72.66m |
| Revenue (TTM) | CHF 236.21m |
Is BSLN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BSLN income statement (TTM) | |
|---|---|
| Revenue | CHF 236.21m |
| Cost of Revenue | CHF 126.63m |
| Gross Profit | CHF 109.58m |
| Other Expenses | CHF 36.92m |
| Earnings | CHF 72.66m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
Feb 17, 2026
| Earnings per share (EPS) | 5.91 |
| Gross Margin | 46.39% |
| Net Profit Margin | 30.76% |
| Debt/Equity Ratio | 79.5% |
How did BSLN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/14 01:59 |
| End of Day Share Price | 2025/12/12 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Basilea Pharmaceutica AG is covered by 19 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Leonildo Delgado | Baader Helvea Equity Research |
| Markus Mayer | Baader Helvea Equity Research |
| Volker Bosse | Baader Helvea Equity Research |